Tandem Diabetes Care is navigating a strategic pivot marked by gross margin recovery to 56.9% in 2026Q2, yet persistent net losses of -$21.2M and a debt-to-equity ratio of 5.67 signal strained financial flexibility.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.10+59.2% vs -$0.25 | $284M+6.7% vs $266M |
Q3 2026 Aug 6, 2026 | -$0.31+3.3% vs -$0.32 | $255M-0.2% vs $255M |
Q2 2026 May 7, 2026 | -$0.30+34.8% vs -$0.46 | $247M+2.8% vs $240M |
Q1 2026 Feb 19, 2026 | -$0.01+80.0% vs -$0.05 | $290M+4.8% vs $277M |
Tandem Diabetes Care NASDAQ: TNDM reported 14% revenue growth in the third quarter of 2026, as higher pump shipments, pharmacy pricing and international sales helped lift gross margin. The company also announced a CEO transition and signaled that a slower-than-expected shift to pharmacy distribution could weigh on revenue growth next year.
Tandem Diabetes Care, Inc. (TNDM) Q3 2026 Earnings Call Transcript
Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.31 per share a year ago.
Benchmark TNDM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Tandem Diabetes Care, Inc. (TNDM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $16.91 | $1.16B | -23.92 | 7.93% | -4.58% | -35.61% | — | |
| $146.51 | $10.15B | 23.74 | 30.73% | 13.45% | 29.48% | — | |
| $79.41 | $30.64B | 30.73 | 15.6% | 19.41% | 36.5% | — | |
| $291.31 | $514.68B | 49.87 | 8.57% | 15.68% | — | 2.26% | |
| $101.80 | $130.7B | 25.01 | 8.43% | 13.93% | 10.51% | 2.78% | |
| $40.31 | $179B | 10.58 | 6.43% | 33.94% | 54.09% | 4.3% |
Tandem Diabetes Care, Inc. (TNDM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Tandem Diabetes Care, Inc. (TNDM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
May 21, 2026·SEC
May 15, 2026·SEC
Get notified when TNDM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Tandem Diabetes Care, Inc. (TNDM) stock FAQ — growth, dividends, profitability & financials explained
Tandem Diabetes Care, Inc. (TNDM) reported $1.08B in revenue over the trailing twelve months. Revenue was $1.01B in fiscal year 2025.
Tandem Diabetes Care, Inc. (TNDM) grew revenue by 6.8% over the trailing twelve months, compared with the twelve months before.
No. Tandem Diabetes Care, Inc. (TNDM) reported a net loss of $49.2M over the trailing twelve months.
Tandem Diabetes Care, Inc. (TNDM) had a return on equity (ROE) of -35.6% over the trailing twelve months. A negative ROE means the company lost money over the period.
Tandem Diabetes Care, Inc. (TNDM) had negative free cash flow of $36.3M over the trailing twelve months.
